key: cord-0859031-kphu47h8
authors: Mehrabadi, Maryam Eskandari; Hemmati, Roohullah; Tashakor, Amin; Homaei, Ahmad; Yousefzadeh, Masoumeh; Hemmati, Karim; Hosseinkhani, Saman
title: Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity
date: 2021-02-05
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2021.111363
sha: a6f83053e56bbc7e8fb99241b41abad86d32e364
doc_id: 859031
cord_uid: kphu47h8

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of COVID-19, is reported to increase the rate of mortality worldwide. COVID-19 is associated with acute respiratory symptoms as well as blood coagulation in the vessels (thrombosis), heart attack and stroke. Given the requirement of angiotensin converting enzyme 2 (ACE2) receptor for SARS-CoV-2 entry into host cells, here we discuss how the downregulation of ACE2 in the COVID-19 patients and virus-induced shift in ACE2 catalytic equilibrium, change the concentrations of substrates such as angiotensin II, apelin-13, dynorphin-13, and products such as angiotensin (1-7), angiotensin (1-9), apelin-12, dynorphin-12 in the human body. Substrates accumulation ultimately induces inflammation, angiogenesis, thrombosis, neuronal and tissue damage while diminished products lead to the loss of the anti-inflammatory, anti-thrombotic and anti-angiogenic responses. In this review, we focus on the viral-induced imbalance between ACE2 substrates and products which exacerbates the severity of COVID-19. Considering the roadmap, we propose multiple therapeutic strategies aiming to rebalance the products of ACE2 and to ameliorate the symptoms of the disease.

SARS-CoV-2 enters the host cells mainly by targeting the Angiotensin Converting Enzyme 2 (ACE2) receptors that is highly expressed in lungs. As ACE2 is expressed in endothelial cells and also throughout the body, COVID-19 can be associated with other symptoms such as hypertension, thrombosis , pulmonary embolism and endothelial dysfunction [1] ACE2, a key enzyme in renin-angiotensin system, binds to a range of substrates including Angiotensin I (Ang I), Angiotensin II (Ang II), apelin 13, neurotensin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , dynorphin A (1-13), β-casomorphin (1-7), and ghrelin [2] . SARS-CoV-2 interacts with ACE2 receptors via the surface glycoprotein S (homotrimer) [3, 4] . ACE2 has been identified as the main receptor for the binding of the SARS-CoV-2 protein S to the host cells. Other studies have shown that transmembrane serine protease 2 (TMPRSS2) [5] , sialic acid receptors and extracellular matrix metalloproteinase may also mediate the entry of the virus to some extent [6] . The N-terminal of the SARS-CoV-2 glycoprotein contains a peptide signal, S1 and S2 subunits. S1 subunit binds to the peptidase domain of ACE2 via receptor binding domain (RBD) and S2 subunit mediates the J o u r n a l P r e -p r o o f fusion of viral membrane and host cell membrane, and facilitates the viral genomes entry into the host cells [3, 7] .

Host protease-induced cleavage and dissociation of protein S are essential for infection [4] .

Protein S is cleaved to a receptor-bound N-terminal S1 subunit and a C-terminal membrane fusion S2 subunit by host proteases such as type II transmembrane serine proteases (TTSPs), HAT, catepsin B and L (pH-dependent endolysosomal protease), elastase, trypsin and furin. A lysosomal protease then cleaves the S2 at S2′ and releases the hydrophobic fusion peptide for integration into the host cell membrane [8, 9] .

Sequence homology studies identified several aminoacid replacement in RBD of SARS-CoV-2 protein S incoparison with SARS-CoV increases the affinity to ACE2 and strengthen the interactions between them. The interaction site is bigger in SARS-CoV-2 than SARS-CoV, as 21 and 17 aminoacides contribute to direct interaction with ACE2, respectively [10] [11] [12] . Shang et al showed that, unlike SARS-CoV, the cells infected by SARS-CoV-2 induce the proprotein convertase furin-mediated protein S pre-activation which increase the affinity of RBD to ACE2. This leads to efficient virus entry into the host cells and also facilitates the escape of the virus from immune machiney. The authors hypothesized that this is the reason for high rate of virus spread [11, 13] . Most of our knowledge about SARS-CoV-2 entery into the cells originates from SARS-CoV. Therefore, it has been suggested that once SARS-CoV-2 bound to ACE-2 receptor, fusion peptide (FP) in S2 subunit interacts with lipid layers in host cell membrane and induces the fusion of virus and host membranes and forms endosomes, in which cysteine proteases like cathepsin B and L and TMPRSS2 cleave protein S and release viral genome in to the cytoplasm [13] . However, much remained to be discovered on how spike protein is cleaved by the proteases.

Xia et al showed that unlike SARS-CoV, an additional RRAR motif exists in SARS-CoV-2 S1/S2 cleavage site. This motif is a furin cleavage site (FCS) that might be cleaved by furin-like enzymes and facilitate virus spread and infection [14, 15] . Huange et al and Hoffmann showed that serine protease TMPRSS2 on host cell membrane might activate SARS-CoV-2 spike protein to enance endosome-mediated viral entry into the cells [4, 11] J o u r n a l P r e -p r o o f ` Based on a previous report virus-bound ACE-2 endocytosis is pH dependent and requires acidic pH (pH 3). Therefore, lysosome and endosome acidic pH activates cathepsin B and L which in turn induce the cleavage of glycoprotein S to S1 and S2 subunits. S1 functions to bind and S2 is used for membrane fusion [16] .

The contribution of a range of proteases to virus-ACE2 interaction can explain many aspects of SARS-CoV-2 pathogenesis. Hoffmann et al. demostrated that the inhibition of TMPRSS2 serine protease by camostat mesylate blocked SARS-CoV-2 infection of lung cells. They concluded that TMPRSS2 plays a role in priming the viral spike protein to enter the cells.

According to the later reaserch, the full inhibition of viral infection is attained when endosomal cathepsin L and B (cysteine proteases) and TMPRSS2 are co-inhibited by E-64d and camostat mesylate respectively. In addition, ammonium choloride strongly inhibited viral entry into the TMPRSS2 ‾ 293T cells implied the ammonium choloride-induced inhibition of endosomal cathepsin L and B cysteine proteases [4] .

In cells, virus amplification takes place by viral RNA polymerase and the viruses then infect the surrounding cells.This might lead to organ dysfunction and faster spread of the virus.

Pattern (PRP) and thus, immune system fails to recognize the viral particles [16] [17] [18] .

The entry of the SARS-CoV-2 and SARS-CoV depends ACE-2 [19] [20] [21] , SARS-CoV-2 downregulates ACE2 expression similar to SARS-CoV [21, 22] . However, sialic acid of the glycoproteins on the surface of host cell may also act as the receptor for hemagglutinin esterase (HE) on SARS-CoV-2. HE contains a carbohydrate binding domain (lectin) linked to a domain with esterase activity. HE binds to sialic acid moieties and facilitates the virus entry. It seems that HE-mediated fusion of the virus and host cell membrane are necessary for the entry of SARS-CoV-2 [23, 24] . ACE2 is the well-known receptor for the entry of SARS-CoV-2 [1] . J o u r n a l P r e -p r o o f ACE2 dysregulation changes the equilibrium of the ACE2-catalyzed reaction. As a result, ACE2

substrates are accumulated while the concentrations of its products are decreased. This might worsen the pathology of the disease and may lead to death. Thereby, ACE2 functions will be reviewed and discussed in detail to elucidate the effects of ACE2 dysregulation upon the entery of the SARS-COV-2.

ACE2 is a cell-surface non-raft protein with the extracellular N-terminal and intracellular Cterminal domains. Binding to SARS-CoV-2 protein S induces the ACE2 internalization [25] .

ACE2 is mainly expressed in cardiac muscle cells, cardiac fibroblasts, the coronary vascular endothelium, kidney, liver, small intestine, testes, brain, lung alveolar epithelial cells, lymphocytes within oral mucosa, enterocytes, arterial and venous endothelial cells as well as arterial smooth muscle cells [26] [27] [28] [29] [30] [31] [32] .

ACE2 is a transmembrane protein, however, a low level of soluble form is detectable in the plasma of patients with COVID-19 [33] . Compared with apical and basolateral localization of ACE, ACE2 is mainly on the apical cell surface [34] . Although ACE2 is a similar carboxypeptidase to ACE (EC 3.4.15.1) with 42% sequence similarity, it is a monocarboxypeptidase (cleaves one amino acid from the substrate) and ACE is a dipeptidylcarboxypeptidase which cleaves a dipeptide at the C-terminal of substrate [35, 36] . Enzyme structure contains a signal peptide, transmembrane domain and Zn 2+ -binding active site. Catalytic site is exposed to vasoactive peptides [35] . ACE inhibitory antibodies do not inhibit the ACE-2, in spite of the similar structures [35, 36] .

In contrast, ACE2 was overexpressed in patients treated with ACE inhibitory antibodies [37, 38] . ACE2 converts Ang II to Angiotensin (1-7) (Ang 1-7), Ang I to angiotensin 1-9 (Ang 1-9), apelin (1-13) to apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , dynorphin A (1-13) to dynorphin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , β-casomorphin (1-7) to β-casomorphin (1-6) [2] . ACE2 is a potential regulator of renin angiotensin system (RAS).

SARS-CoV-2 interaction with ACE2, interferes RAS and enhances the severity of acute respiratory symptoms [39] . Since SARS-CoV-2 infection is associated with a downregulation of ACE2 expression [21] , this can exacerbates the COVID-19 symptoms. For better understanding of the harmful effects of the accumulation of ACE2 substrates and decrease in the concentrations of the products due to the ACE2 viral-induced dysregulation, we have a closer look at the substrates and products (Table 1) . In this review, we focus on the consequences of the SARS-CoV-2 induced imbalance between ACE2 substrates and products aiming to discover the relation among substrates accumulation, decreased products and disease complications to propose therapeutic strategies.

In RAS, Angiotensin I is produced from angiotensinogen by the action of renin ( released from kidney juxtaglomerular cells) [40] . Ang I is converted to Ang II by the catalytic activity of ACE particularly in pulmonary endothelial, plasma, kidney, brain and heart coronaries. In rat model, Ang II, with a half-life of approximately 16 seconds in plasma [ 14 ] , is quickly converted to either Ang (1-7) by ACE2 or Ang III by angiotensinases [42] . Ang II is an active octapeptide which triggers its physiological functions by binding to Angiotensin II receptor type 1 (AT-1) ( Figure 1 ), AT-2 and AT-4 receptors [43] . The main functions of AT-1 mediated Ang II [44] are vasocontraction [45] , inotropy and cardiac regeneration (via myocard receptors), sympathetic nervous system enhancement [46] , vasopressin diffusion, regulation of peripheral sympathetic J o u r n a l P r e -p r o o f nervous system and pituitary, regulation of aldosterone secretion (via receptors in adrenal glands) [47] . AT-2 receptors are widely expressed in emberyoinc tissues, however their expression is limited to adrenal gland, vascular endothelial, brain, kidney and ovary, which acts as vasodilator by releasing bradykinin and nitric oxide [48] . AT-2 mediates anti-inflammatory in vitro and in vivo [49, 50] and anti-proliferating responses in rat pheochromocytoma cell line [51, 52] which attenuates AT-1 signaling in turn . Moreover, it seems that AT-4 regulates extracellular matrix in central nervous system and modulates oxytocin diffusion [53, 54] .

Ang II stimulates inflammatory responses, via AT-1, in leukocytes, endothelial cells and smooth muscle cells by activating NF-κB which altogether enhance the transcription of TNF-α, IL-1 and Interleukin 6 (IL-6) [55] , adhesive molecules such as E-selectin and P-selectin, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), teefeffi yefkemtfff of eiefe eetfeeokkoieec e actors [56] . These functions of Ang II are consistent with the findings from COVID-19 patients where SARS-CoV-2 entry to pulmonary cells was associated with high secretion of inflammatory cytokines like IL-1β, IL-6 and TNFα [1, 57] .

Among all, IL-6 is known to be one of the strongest predictors of death during hospitalization [58] . Downregulation of ACE-2 in COVID-19 patients can lead to Ang II accumulation [57, 59] .

Studies on patient samples and animal models have shown that Ang II binding to AT-1 can further internalize ACE2 through extracellular signal-regulated kinases (ERK1/2) and P38 mitogen-activated protein kinase (MAPK) signaling and hence downregulates ACE2 [60, 61] .

Hypertension in COVID-19 patients [62] [63] [64] might be severed by Ang II accumulation which activates proinflammatory signaling [65] . Clinical studies have shown that arterial pressure is correlated to increased plasma inflammatory mediators and vascular inflammation. In J o u r n a l P r e -p r o o f hypertensive patients circulating monocytes, lymphocytes and pro-inflammatory cytokines such as TNF-α, IL-6 and C-reactive protein (CRP) are increased [66] [67] [68] .

Accumulated Ang II can be metabolized to Ang IV by aminopeptidase A [69] . Ang IV binds to AT-4 receptor [54] . Accumulation of Ang II ( in mice model) and Ang IV ( in rat model) can

increase the likeliness of thrombosis by increasing the plasminogen activator inhibitor-1 (PAI-1) [70] [71] [72] . Thrombotic role of Ang II can be explained by overexpressing and activating endothelin-1 as PAI-1 activator [65, 73] . Ang II-stimulated inflammation influences the vascular permeability in rat endothelial cells [74] , alters vascular morphogenic responses, leukocyte attachment to endothelium (in rat model) [75] and platelet accumulation in human platelet rich plasma ( in vitro study) [76, 77] . Hypertension is prevalence among the COVID-19 patients and might be induced by Ang II accumulation associated with accumulation of platelets, platelet dysfunction , deficient fibrinolysis and coagulation [71, 78] . Therefore, thrombosis in COVID-19 patients can be attributed to harmful effects of Ang II accumulation due to dysregulation of ACE2 after entry of the SARS-CoV-2 into host cells [8, 79] . COVID-19 patients have more or less impaired coagulation system which increases the rate of ischemic mortality [80, 81] . Acute pulmonary embolism in COVID-19 patients is one of the important predictor of clinical deterioration during viral pneumonia [82] [83] [84] . Therefore, a constant checking of the coagulation markers such a Prothrombin Time/Partial Thromboplastin Time (PT/PTT), fibrinogen, D-dimer and prescribing the anticoagulation agents like heparin has been recommended for patients with D-dimer value above normal range (4 times higher in COVID-19 patients) [1] .

Ang II also acts as a pathologic mechanism in angiogenesis during hypoxia. Ang II upregulates angiopoietin-2, the factor that binds to TEK receptor tyrosine kinase (Tie2) and

induces angiogenesis. At the early stages of angiogenesis, angiopoietin-2 antagonizes Tie2 and J o u r n a l P r e -p r o o f inhibits angiopoietin-1/Tie2 signaling axis. Cornea micropocket assay has showed that the angiopoietin induces neovascularization in mice mediated by vascular endothelial growth factor (VEGF) [85, 86] . This allows VEGF and other growth factors to enhance the migration of endothelial cells, and form new vessels [85, 86] . Consequently, angiopoietin-1 is increased while angiopoietin-2 is decreased [87, 88] . However, angiopoietin-1 activates Tie2 and induces endothelial survival as well as vessel maturation [87, 88] . Therefore, the ratio of angiopoietin-2 to angiopoietin-1 is well controlled during angiogenesis and shifts toward either of the proteins associated with pathological conditions [87, 88] . Angiopoietin-2 is increased during acute respiratory distress syndrome (ARDS) in COVID-19 patients [89] . This is consistent with the increased (angiopoietin-2)/(angiopoietin-1) ratio in ALI/ARDS patients. Increased Angiopoetin-2 can be a prognosis marker for lethality [90] . Ang II upregulates angiopoietin-2 and increases angioprotein-2 as well as VEGF expression and thus play a key role in increasing vascular permeability in patients with acute pulmonary injury [91] . Vascular permeability is increased in patients with acute respiratory syndrome as a result of hypoxia-induced VEGF expression [92] . and focal adhesion tyrosine kinase (FAK) induced inflammatory responses [93] . Angioprotein-2 has been shown to induce inflammation and cell death during hypoxia in vivo as well as epithelial necrosis in mouse lung epithelial cell and mice in vitro (hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death).

These raise the possibility that Ang II-induced angiogenesis and high vascular permeability worsen the pathology of the COVID-19 [8] . Regarding the role of Ang II in the induction of oxidative stress, Ang II phosphorylates c-Src, [the regulator of NOX (a family of of NAD(P)H oxidases) that is the main source of reactive oxygen species (ROS)] [94, 95] . In addition, Ang II facilitates ROS generation by the mitochondrial potential depolarization [96] . There is evidence J o u r n a l P r e -p r o o f that Ang II downregulates the ROS scavengers and hence increases ROS [97] . ROS activates redox-sensitive transcription factors like activator protein 1 (AP-1) and NF-κB [98] , leading to vascular permeability, leukocyte infiltration, and etc [98] . As oxidative stress is generated during coronavirus induced ADRS, COVID-19 patients show the aforementioned symptoms due to Ang II accumulation and impaired ACE2 signaling axis, less access of endothelial cells to nitric oxide (NO) and oxidative stress [99] . Moreover, the increased ROS during oxidative stress can upregulate VEGF in macrophages and endothelial cells [100, 101] . ROS induces Hypoxia-Inducible Factor 1-alpha (HIF1-α) and Ets-1 and resulting in VEGF upregulation [102] . Byproducts of ROS such as lipid peroxide can interact with VEGFR2 and induce angiogenesis in vivo [103] . Multiple in vitro studies on normal and tumor cell types have shown that the lipid oxidation products increase VEGF which induces angiogenesis in association with IL-8 and COX-2 products [104] . Animal studies have shown that lipid oxidation products can induce angiogenesis through VEGF-independent Toll-like receptor (TLR) 2/MyD88 dependent signaling ( Figure 1 ) [105] .

As discussed aboved, Ang II can affect the severity of COVID-19. A recent study in human ( non-hypertensive patients) showed that there is a correlation between the plasma concentration of Ang II and severity of COVID-19 [ 95 ] . Since it negatively regulates the activity of ACE2 and also plays a role in hypertension, infalamation, oxidative stress and angiogenesis whose accumulation may lead to severity of COVID-19.

J o u r n a l P r e -p r o o f

Ang II is mainly degraded by ACE2 and to some extent by prolylcarboxypeptidase (PRCP) and prolyloligopeptidase (POP/PEP/ PREP/PE), where these carboxypeptidases remove the Cterminal phenylalanine from Ang II [33] . In contrast to Ang II, Ang (1-7) is a biologically active peptide and acts by binding to MAS receptor and inhibiting the vasocontraction, angiogenesis and inflammation ( Figure 2 ) [106, 107] .

In addition, Ang (1-7) has showed beneficial effects on hypertensive patients. It also alters renal water retention, and enhances vasodilation [108] . Ang (1-7) suppresses angiogenesis, suggesting that Ang (1-7) can be an endogeonous regulator of cell growth. It should be noted that Ang (1-7) reduces VEGF and cosequently induces the angiogenesis in xenograft mice model of lung cancer. Altogether, Ang (1-7) reduces the expression of VEGF, placental growth factor (PlGF), HIF-1α and VEGF receptors in human nasopharyngeal carcinoma xenografts in nude mice model. These processes have been further confirmed by in vitro studies [109, 110] . In vivo study on prostate cancer model has showed that Ang (1-7) decreases angiogenesis by reducing the expression of PLGF and VEGF and increasing the expression of fms-like tyrosine kinase-1 (sFlt-1) [111] . Anti-inflammatory functions of Ang (1-7) are induced by binding to MAS receptors on leukocytes [106] Anti-inflammatory and antifibrotic activities of Ang (1-7)/Mas are regulated by reducing the leukocyte migration, downregulation of pro-inflammatory cytokines, and reduction of tissue fibrosis factors [106] . In patients with kidney disease, Ang (1-7)/Mas attenuates inflammatory responses by reducing neutrophil influx, downregulating CXC chemokine ligand (CXCL), IL-6, TNF-α, IL-1b, Endothelin-1 (a vasocontractor) and monocyte chemoattractant protein-1 (MCP-1, a key chemokine responsible for white blood cells migration) [112] . Considering the renal failure in COVID-19 patients, administration of Ang (1-7) might J o u r n a l P r e -p r o o f help the recovery of the patients by its anti-inflammatory and anti-fibrotic effects [113] . Ang (1-7) decreases oxidative stress and suppress NF-κB and thus improves permanent middle cerebral artery occlusion [114] . In addition, intracerebroventricular administered Ang (1-7) in brain ischemic mice inhibited NF-κB activity which in turn is associated with downregulation of TNFα, IL-1β and cyclooxygenase-2 (COX-2) and hence could rescue the brain [115] . COVID-19 damages patients' nervous system as virus is able to attack nervous system suggesting the use of Ang (1-7) to reduce the clinical complications [115] . Study on heart tissue (Sprague-Dawley rats) has shown the beneficial role of Ang (1-7) in maintaining the cardiovascular hemostasis and protection against heart diseases. In heart (Sprague-Dawley rats), Ang (1-7) reduces the expression of inflammatory cytokines such as TNF-α and IL-6 and increases IL-10 [116] . As ARDS is caused by SARS-CoV-2 infections, Ang (1-7) can be a useful drug candidate for improving lung function. Reduction in the concentration of Ang (1-7) in COVID-19 patients is due to dysregulation, internalization and shedding of ACE2. Ang (1-7) has anti-thrombotic effect by releasing an antithrombotic factor NO via MAS receptor-induced signaling. When concentration of Ang II is low, Ang (1-7) binds to AT2R and increases the concentration of NO and prostacyclin in plasma and these factors facilitate clot formation by activating the platelets [115, [117] [118] [119] [120] .

Considering the anti-inflammatory and anti-hypertensive roles and stimulatory effect on clot formation, Ang (1-7) might be beneficial for COVID-19 patients to protect them against thrombosis ( Figure 2 ). J o u r n a l P r e -p r o o f

Ang (1-9) is produced from Ang II in a reaction catalyzed by ACE2 or catepsin A [121] . Ang (1) (2) (3) (4) (5) (6) (7) (8) (9) binds to AT2R, inhibits the Ang II-AT1R signaling axis [122] and balances the vasoconstrictive/proliferative to vasodilatory/antiproliferative axis and consequently, improves cardiovascular conditions [123] . AT2R-derived signaling functions in cell differentiation, vasodilation and reduces the cell proliferation, inflammation and fibrosis [124] .

During post-myocardial infarction, Ang (1-9) improves cardiovascular conditions and left ventricular systolic performance [124] [125] [126] . In cardiomyocytes, similar to Ang (1-7), Ang (1-9) exerts positive inotropic effects by increasing calcium transient amplitude and contraction force, and anti-ventricular hypertrophy effect ,in vivo and in vitro ( in animal models) [124] . Ang (1) (2) (3) (4) (5) (6) (7) (8) (9) reduces blood pressure by affecting endothelial cells [127] . The vascular enhancement is attributed to the release of NO and arachidonic acid in endothelial cells, which improves bradykinin-induced endothelial repair (in vitro study on human right atrial and left ventricular tissues) [128] . Ang (1-9) also reduces tissue fibrosis especially in the heart and the lungs [122, 129] . Pulmonary fibrosis has been demonstrated in COVOD-19 patients [130] , suggesting that Ang (1-9) might be a potential treatment for lung fibrosis. SA Cha et al. have shown that Ang (1-9) downregulates the expression of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, MCP-1 in pulmonary arterial in monocrotaline (MCT)-induced pulmonary hypertensive rats [131] . Furthermore, Ang (1-9) downregulates proinflammatory cytokins such as IL-6, IL-1β, TNF-α, MCP-1 in pulmonary arterial hypertension in rat model [ 434 ] . In hypertensive rats, Ang

(1-9) affaects heart, aortic wall, and kidney independent of AR2R

Therefore, it is anticipated that Ang (1-9) synergizes Ang (1-7) and suppresses the inflammation in COVID-19

J o u r n a l P r e -p r o o f patients. Low level of Ang (1-9) and the consequent complications can be attributed to downregulation of ACE2. (Figure 3 ).

Apelin (1-13) is a member of apelin family, named after first extraction from bovine stomach extract. This peptide acts as a ligand for previously-identified GPCR AR (APJ) receptors. Apelin in mammalian has 77 amino acids and is engaged to the production of several peptides with various lengths (12, 13, 17 and 36 residues in length) [133, 134] .

It is the second catalytic substrate for ACE2 with the powerful positive inotropic actions [133] . The isoforms can be generated by the processing enzymes. Apelin-13 is converted to Pyrapelin-13 by spontaneous rotation of N-terminal glutamine which produces a more stable isoform with higher half-life [134] [135] [136] [137] [138] .

Apelin-13 is the most abundant isoform in plasma, heart and brain [134] . Apelin and its receptor APJ are expressed in CNS, cardiovascular, circulation, digestive and reproductive systems, fat tissue and skeletal muscles [139, 140] .

It seems that the main physiological role of apelin is the vascular tone and cardiac contraction modulation [139, 140] . In rat model, apelins modulate cardiocontraction and vascular tone likely via activation of protein kinase Cε (PKCε) and ERK1/2 signaling pathway [141] . In addition, it has been suggested that apelin upregulates VEGFA, VEGFR2 (kdr Kinase Insert Domain

Receptor), angiopoetin-1, Tie2 and endothelial nitric oxide synthase (eNOS) as angiogenic and antifibrotic factors to target the heart (in rat model of post-MI) [142] . Apelin (1-13) also plays anti-apoptotic roles via phosphatidylinositol-3-kinase (PI3K)/Akt, ERK1/2, caspase signaling and autophagy [143] . Hypoxia induces the expression of apelin via HIF-1α-mediated mechanism in smooth muscle cells in the lungs [144] .

Moreover, expression of apelin is induced both directly and indirectly by hypoxia and VGEF in endothelial cells respectively [144, 145] . Owing to ACE2 downregulation [21, 22] has been reported to induce angiogenesis in heart, retina and lungs [146] [147] [148] [149] [150] .

correlated to the level of apelin. Based on the previous research, during oxidative stress, apelin

(1-13) increases antioxidant scavengers and reduces mitochondrial ROS [151] [152] [153] [154] .

As COVID-19 is a severe respiratory disease, it is hypothesized that apelin-13 is increased in the plasma of the patients with COVID-19. Some studies have shown that administration of apelin (1-13) inhibits NF-κB pathway which reduces proinflammatory cytokines IL-6 E, TNF-α and IL-1β [154, 155] .

Moreover, LPS-treated mice showed that apelin (1-13) preventes the nuclear migration of NF-κB 65P and subsequently inhibites the NF-κB signaling and the macrophage infiltration [154] .

Interestingly, apelin (1-13) prevents the activation of LPS-induced NLR family pyrin domain containing 3 (NLRP3) inflammation in mice lungs and hence reduces the inflammatory cytokines [152, 154] . It can be imagined that due to the low half-life, anti-inflammatory and antioxidant properties, endogenous apelin (1-13) is not quite stable.

One of the most remarkable roles of apelin (1-13) is to regulate blood pressure. It has been found that APJ receptor interacts with AT1R to decrease the affinity of Ang II binding to AT1R.

Therefore, it acts as a negative allosteric regulator for AT1 and negatively regulates Ang II function during hypertension [156] . Moreover, apelin upregulates the expression of ACE2 and reduces the concentration of Ang II (in vitro and in vivo studies: in mice) [157, 158] .

Studies on the administration of apelin, to compare the effects of apelin (1-12), apelin (1-13) and

apelin (1-36) on arterial pressure, showed that apelin (1-12) is most potent for arterial pressure reduction in anesthetized mice [159] . Therefore, it is hypothesized that downregulation of ACE2 by SARS-CoV-2 in COVID-19 patients can reduce Apelin (1-12), the product of ACE2.

Considering the low half-life of apelin (1-13), it might be accumaulated in body upon the entery of SARS-CoV-2 into the cells ( Table 2 ).

Hydrolysis of phenylalanine residue at the C-terminal decreases the half-life of apelin (1-13) in the circulation resulting in the production of apelin (1-12) [157] . Removal of phenylalanine from apelin (1-13) reduces the affinity of the produced apelin (1-12) to APJ receptor three times without significantly changing the biological activity [160] .

to the length of the peptide and therefore, apelin-12 is a highly active isoform [159] . However, the length of at least 12 residues seems to be essential for the biological activity of the apelin derivatives because apleins with 9, 10 and 11 residues are biologically inactive. The half-life of apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) in human plasma is 10-15 minutes [161] while it is about 3 and 8 minutes for apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) in rats [162] and humans plasma [163] , respectively. Apelin knockout mice showed J o u r n a l P r e -p r o o f hypertension and age-related impaired ventricular contraction similar to the cardiac phenotype of ACE2 knockout mice [164] . Apparently, stable responses following apelin (1-13) injection is due to ACE2-induced apelin (1-13) cleavage and the production of apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Studies on rats with coronary artery occlusion have shown the apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) in heart which reduced the mean arterial pressure [165] . Apelin (1-12) injection following local ischemia ameliorates myocard infarction and damage to heart membrane in rats [166] .

In humans, apelin (1-12) increases blood pressure in a dose-dependent manner. Apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) induces the overexpression of ACE2 [158] . On the other hand, SARS-CoV-2 infection is associated with a downregulation of ACE2 expression [21] .Therefore, it has been suggested that induction of the expression of ACE2 particularly apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) , would lead to increase in the concentrations of Ang (1-7) and Ang (1-9) which in turn might promote the recovery from COVID-19. Since acute cardiac injury is among the most common complications in COVID-19 [167] , apelin (1-12) reduction may induce cardiac injury as it normally plays protective roles in heart tissue (Table 3 ). This reduction also causes cardiovascular failure, as it reduces systemic oxygenation during pneumonia and activates T cells and immune signaling [168] .

Downregulation of ACE2 in COVID-19 might attenuate the immune response to SARS-CoV-2 due to decrease in the concentration of apelin (1-12) which can explain cardiac injury by taking into account the protective role of apelin (1-12) for heart tissue. It is crucial to investigate the effects of Apelin (1-12) and Apelin (1-13) on the repair of endothelial cells as immunoreactivity of [Pyr1] apelin-13 (1-12)-like has been discovered in neighboring endothelial cells [161] .

Dynorphins (endogenous opioid neuropeptides) are the ACE2 substrates with pain relieving effects [169, 170] .

Dynorphins binds to κ-opioid receptors and act as inhibitory neurotransmitters and induce pain desensitization [171] . Dynorphin A (1-13) is a breakdown product of dynorphin A which is synthesized as preprodynorphin [172] . Apart from pain relieving roles, high concentration of dynorphins can induce hyperalgesia and allodynia or even the production of neurodegeneration metabolites [173] . . Since

, it is thought that production of dynorphin A might be increased more in COVID-19.

Finally, dynorphin A (1-12) is produced by the cleavage of dynorphin A (1-13) by ACE2 [170, 182] . Dynorphin A (1-12) is one of the main metabolites of dynorphin A (1-13) in human CSF and plasma which binds to κ-opioid receptor with the less affinity than dynorphin A (1-13) [183, 184] .Half-life of dynorphin A (1-12) is 1.9 minute (more than dynorphin A1-13, half life :0.9 minute) (in human blood and plasma) [185] . It is anticipated that its accumulation shows only mild side effects, ACE2 dysregulation induced by the entry of SARS-CoV-2 into the cells decreases the concentration of dynorphin A (1-12) and might lead to loss of its counterbalancing effects against accumulated dynorphin A (1-13).

Adoptive and innate immunities play a key role against SARS-CoV-2, however, the virus can induce hyperinflamation or cytokine storm [57] . Although different factors induce cytokine storm, studying the dysregulation of ACE2 and correlation with immune responses seems interesting ( Figure 5) . A previously-published study has reported that downregulation of ACE2 in macrophages in COVID-19 patients increases the inflammatory cytokine and production of NO. On the other hand, Ang II induces cell proliferation and cytokine production implying the role of Ang II in regulating the cell signaling in inflammation and immune-related diseases [186] . IL-2 is an immune cytokine that stimulates the proliferation of T cells [187] . Studies on

Jurkat T-cells showed that Ang II-ATR1-ERK axis activates lymphocyte T and leads to production of IL-2 [186] . For instance, AT1R found on the surfaces of various immune cell and T cells contains endogenous RAS and thus express renin, renin receptor, angiotensinogen and ACE2 [188] . Ang II-AT1R axis in T cells regulates activation of T lymphocytes and secretion of IL-2, IFN-γ and reduces IL-4 [189, 190] . The axis also induces differentiation of Th0 to Th1 cell through activation of AT1R-PKA-proteasome pathway [191] . Th1 is responsible for the J o u r n a l P r e -p r o o f production of IL-1B, IFNγ, CXCL10, and CCL2 [192] . In human Jurkat T cells (in vitro study), Apelin-APJ system upregulates the expression of CD69 and CD25 on the surface of T lymphocytes and stimulates the cells proliferation and activity [193] . Apelin (1-13) suppresses IFN-γ, IL-2 and IL-4 in activated T lymphocytes in mice [194] . AT1R is also expressed on macrophages when monocytes are differentiated to macrophages [195] and upregulates inflammatory cytokines such as TNF-α, IL-1b, IL-6, and IL-10 and produces ROS through NF-κB and AP-1 pathway [196] . Apelin (1-13) promotes growth and differentiation of macrophages by binding to APJ through ERK1/2 and mitogen-activated protein (MAP) kinase pathways and by inhibition of apoptosis [197, 198] . Apelin (1-13) also reduces the production of cytokine and ROS in macrophages and prevents the conversion of macrophage to foam cells [199] . Moreover, dendritic cells express AT1R and hence activate NF-κB for the production of proinflammatory cytokines [200, 201] .

Studies on DC2.4 cells, a murine bone marrow-derived DC line, showed that Ang II activates dendritic cells in part through p65 / NF-κB ،ERK2/1 and STAT1 [202] .

Furthermore, dynorphin A induces the secretion of IL-1, TNFα, macrophage-mediated phagocytosis, chemotaxis in mononuclear cells and neutrophils, and reduces the release of NO [203] . The anti-inflammatory functions of Ang (1-9) and Ang (1-7) have been already discussed, however, there is not much information about their functions on immune cells. Ang (1-7) has been shown to induce macrophage-mediated anti-inflammatory responses via MAS axis (in murine models of autoimmune neuroinflammation and atherosclerosis) [204] . AT2R, a receptor for Ang (1-9), was found on T cells and NK cells and anti-inflammatory function of AT2R ligands or agonists is dependent on the formation of epoxyeicosatrienoic acid and direct inhibition of NF-κB inflammatory signaling. In addition, lymphopenia is one of the most J o u r n a l P r e -p r o o f informative diagnostic markers of COVID-19 which is produced as a consequence of cytokine storm [205] . The cytokine storm and increased inflammatory cytokines like TNF-α and IL-6

induce apoptosis and necrosis in T cells [206] . In patients with COVID-19, the increased cytokines were correlated to decreased T lymphocytes and according to the function of Ang II, it is involved in the production of these inflammatory cytokines and acts to reduce lymphocytes [207] . On the other hand, Ang 1-7, Ang 1-9 can be effective as anti-inflammatory substance on preventing the reduction of lymphocytes.

Moreover, pyroptosis, a novel inflammatory form of programmed cell death following infection, is the other cause of lymphopenia induced by SARS-CoV [208] .

Pyroptosis is a much faster process than apoptosis and is associated with diffusion of proinflammatory factors [209] . Pathogen-associated molecular patterns (PAMPs) binding to pattern recognition receptors (PRR) such as nitric oxide synthase and NLRP3 on host cells, activate caspase-1, a key component of innate immunity which in turn leads to cell perforation, inflammation, cell lysis and secretion of IL-1β and IL-18 [96] . Similarity between SARS-COV and SARS-COV-2 on one hand and increased IL 1β as a marker for pyroptosis on the other hand suggests that pyroptosis may explain the lymphopenia in COVID-19 patients [92, 118] . It could be initiation of inflammatory signaling induced by increased Ang II as well as pyroptosismediated release of cytokines ( Figure 5 ) [201] . In sum, these conditions can exacerbate the inflammation induced by the imbalance between ACE2 substrates and products in the COVID-19 patients.

Considering the key role of ACE2 as a functional receptor for SARS-CoV-2, targeting the receptor to block the virus entry is studying [210] . We sugest that downregulation of ACE2 can J o u r n a l P r e -p r o o f be one of the main causes of SARS-CoV-2 symptoms. COVID-19 severity can be changed by reduction in ACE2 products such as Ang (1-7), Ang (1-9), apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) and accumulation of substrates such as apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) and Ang II [211] . smell induced by coronaviruses might be attributed to virus entry into the nervous system and subsequent hypoxia-induced damages following the pulmonary disorders and the production of inflammatory cytokines (cytokine storm) [215] [216] [217] . It has been suggested that targeting ACE2 expression can be used as a treatment for COVID-19 and thus, ARB and ACE inhibitors (ACEi)

have been used to increase the level of ACE2 but failed to treat [211, 218] . It should be noted that ACEi have been already used in asian brain ischemic patients [219] as well as Parkinson disease which questions the negative effects of ACEi [220] [221] [222] [223] .

Considering the severe thrombotic complications in the COVID-19 patients [224] , it has been suggested that the use of anti-coagulants may reduce the symptoms at the expense of serious side effects. Inflammatory responses can play a key role against SARS-CoV-2 by removeing J o u r n a l P r e -p r o o f infection, however, hyperinflamation or cytokine storm can lead to death, and thus the use of non-steroidal anti-inflammatory drugs is not a safe and promising therapeutic approach to treat COVID-19. Considering the anti-thrombotic, anti-hypertensive and anti-oxidative stress properties of ACE2 products such as Ang (1-7) and cardiovascular protective function of Ang (1-9), we suggest the use of the more stable analogs of these compounds to reverse the harmful effects of Ang II accumulation induced by dysregulation of ACE2. As inflammation, vascular failure, blood pressure and von Willebrand factor play roles in vascular thrombosis [225, 226] ,

Ang (1-9) might have protective role against vascular thrombosis in COVID-19 patients. In addition, Ang (1-7) may exert more efficient protection against COVID-19 than recombinant soluble ACE2 or AT1 blockers, however this needs to be investigated and clinically evaluated.

We also suggest that the administration of apelin (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) can be tested for the treatment of the COVID-19 due to prolonged half-life, higher affinity to AT1 and higher expression in 

This research was done without any financial support in the form of grant or otherwise.

The authors declare that they have no conflict of interest. Ang I: angiotensin I, Ang II angiotensin II, Ang 1-7. angiotensin 1-7, ACE: angiotensin-converting enzyme, ACE2: angiotensin-converting enzyme2, AT1R: Angiotensin II receptor type 1, AT4R: Angiotensin II receptor type 4, PAI-1: Plasminogen activator inhibitor-1 ROS: Reactive Oxygen Species, VEGF: Vascular endothelial growth factor, ARB drugs: angiotensin II receptor blocker drugs, ACEi drugs: Angiotensin-converting enzyme inhibitor drugs, BBB: blood-brain barrier. ACE2: angiotensin converting enzyme2, Ang 1-9: Angiotensin 1-9, Ang 1-7: Angiotensin 1-7, MasR: mitochondrial assembly receptor, TGF-β: Transforming growth factor beta. Figure 3 . Ang 1-9 functions in human organs. ACE2 converts Ang1 to the Ang 1-9 and the latter acts through its receptor (AT2R). SARS-CoV-2 downregulates the expression of ACE2 which ultimately reduces the concentration of Ang 1-9. The decrease in the concentration of Ang 1-9 results in the loss of its beneficial functions in several organs in patients with COVID-19 (Created in BioRender.com).

ACE2: angiotensin converting enzyme2, Ang I: Angiotensin I, Ang 1-9: Angiotensin 1-9, AT 2 R;

Angiotensin II receptor type 2, MI: myocardial infarction, vWF: von Willebrand factor, α-SMA:

α-smooth muscle actin. 1: Angiotensin I, 2: Angiotensin 1-9, 3: Angiotensin 1-7, 5: angiotensin II type-2 receptor, 6: angiotensin II type-1 receptor, 7: Mas receptor, 8: apelin receptor, : κ-opioid receptor, 10: N-Methyl-D-aspartate receptor. 

Mice and HK-2 cells Antagonist of the TGF-β1/Smad 9 pathway. ↓matrix collagen production and improved tubulointerstitial lesions.

Retardation of CKD progression.

[238]

Cerebral I/R injury Rat and neurons cells Activation of Gαi/Gαq-CK2 10 signaling attenuates eIF2 11 -ATF4 12 -CHOP 13 -mediated neuronal apoptosis.

Protection of neurons against I/R injuryinduced apoptosis, facilitation of post-stroke recovery [239] Parkinson's disease Human neuroblastoma SH-SY5Y cell ↓ ROS and the inhibition of caspase-3 and release of cytochrome c

Protective effects against dopaminergic neural toxicity by antioxidant and antiapoptotic properties. [240] 1: microRNA, 2: Fibroblast growth factors, 3: Fibroblast growth factor receptors, 4: Nuclear factor kappa B, 5: NLR family pyrin domain containing 3, 6: Reactive oxygen species, 7: Connective tissue growth factor, 8: Transforming growth factor beta, 9: Mothers against decapentaplegic homolog 4, 10: Casein kinase II, 11: Eukaryotic initiation factor 2, 12: Activating transcription factor 4, 13: C/EBP homologous protein. Reduction of irreversible cardiomyocyte damage, improvement of cardiac dysfunction, enhancement of metabolic restoration and membrane integrity.

[244]

Cerebral infarction Mice Improvement of the neurobehavioral score and brain edema. Inhibition of the morphological changes and apoptosis of neuronal cells, Activation of caspase-3. ↑ Bcl 6 -2. ↓Bax 7 , ↓caspase-3, ↓p-JNK 8 and p-p38 9

Inhibition of the JNK and P38/MAPK 10 signaling pathway. protection to neurons [245] 1: Phospholipase C, 2: Protein kinase C, 3: Phosphatidylinositol 3-kinase, 4: Mitogen-activated protein kinase kinase, 5: Ischemia/reperfusion, 6: B-cell lymphoma 2, 7: B-cell lymphoma protein 2 -associated X, 8: C-Jun N-terminal kinase, 9: Phosphorylated p38, 10: Mitogen-activated protein kinase.

J o u r n a l P r e -p r o o f

Is COVID-19 an endothelial disease? Clinical and basic evidence

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Structural basis for human coronavirus attachment to sialic acid receptors

Nervous system involvement after infection with COVID-19 and other coronaviruses

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro

Structural basis of receptor recognition by SARS-CoV-2

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

Cell entry mechanisms of SARS-CoV-2

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Chloroquine as a potential treatment and prevention measure for the 2019 novel coronavirus: a review

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Molecular immune pathogenesis and diagnosis of COVID-19

COVID-19 and the RAAS-a potential role for angiotensin II?

Coronavirus disease 2019 (covid 19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection

Single-cell analyses reveal SARS-CoV-2 interference with intrinsic immune response in the human gut

Linking ACE2 and angiotensin II to pulmonary immunovascular dysregulation in SARS-CoV-2 infection

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor

Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks

Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus

Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system

Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS

Angiotensin-Converting Enzyme 2 Is a Critical Determinant of Angiotensin II-Induced Loss of Vascular Smooth Muscle Cells and Adverse Vascular Remodeling

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent

Angiotensinconverting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors

Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism

SARS-CoV-2 receptor and regulator of the reninangiotensin system: celebrating the 20th anniversary of the discovery of ACE2

The half lives of angiotensin II, angiotensin II amide, angiotensin III, Sar1 Ala8 angiotensin II and renin in the circulatory system of the rat

Endothelial metabolism of angiotensin II to angiotensin III, not angiotensin (1-7), augments the vasorelaxation response in adrenal cortical arteries

Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors

Angiotensin II receptors and drug discovery in cardiovascular disease

Role for G12/G13 in agonist-induced vascular smooth muscle cell contraction

Specific angiotensin II binding sites in the rat stellate and superior cervical ganglia

Recent progress in understanding aldosterone secretion

AT2 receptor dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions

Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor κB

Angiotensin AT 2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production

The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells

Angiotensin II's antiproliferative effects mediated through AT2-receptors depend on down-regulation of SM-20

Angiotensin in critical care

Mechanism of Ang II involvement in activation of NF-κB through phosphorylation of p65 during aging

Direct evidence of leukocyte adhesion in arterioles by angiotensin II

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19

Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients

Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin II, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin

Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway

Hypertension and COVID-19

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Angiotensin II induces endothelin-1 gene expression via extracellular signal-regulated kinase pathway in rat aortic smooth muscle cells

Inflammation, immunity, and hypertensive end-organ damage

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

Novel clinical markers of vascular wall inflammation

Renal expression of aminopeptidase A in rats with two kidney, one clip hypertension

Roles of Coagulation and Fibrinolysis in Angiotensin II Enhanced Microvascular Thrombosis

Angiotensin IImediated microvascular thrombosis

Angiotensin II enhances thrombosis development in renovascular hypertensive rats

Angiotensin II enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A receptor

Angiotensin II inhibits the protein expression of ZO-1 in vascular endothelial cells by downregulating VE-cadherin

Upregulated expression of rat heart intercellular adhesion molecule-1 in angiotensin II-but not phenylephrine-induced hypertension

Role of Angiopoietin-2 in vascular physiology and pathophysiology

Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan

Mechanisms underlying the cerebral microvascular responses to angiotensin II induced hypertension

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

COVID-19 complicated by acute pulmonary embolism

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Similarities between community-acquired pneumonia and pulmonary embolism

Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells

Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization

Angiopoietin-2: modulator of vascular permeability in acute lung injury?

The Ratio of Angiopoietin-2 to Angiopoietin-1 as a Predictor of Mortality in Acute Lung Injury Patients

Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial

The role of angiogenic factors and their soluble receptors in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) associated with critical illness

Role of Angiopoietin-2 in vascular physiology and pathophysiology

Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: identification of a 5′ enhancer

VEGF-induced vascular permeability is mediated by FAK

Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR

Reactive oxygen species and endothelial function-role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases

Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Gαq overexpression-induced heart failure

Downregulation of manganese superoxide dismutase by angiotensin II in cardiac fibroblasts of rats: Association with oxidative stress in myocardium

Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade

Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection

Oxygen tension regulates the expression of angiogenesis factor by macrophages

Regulation of VEGF-induced endothelial cell migration by mitochondrial reactive oxygen species

Redox balance dynamically regulates vascular growth and remodeling

A role for VEGFR2 activation in endothelial responses caused by barrier disruptive OxPAPC concentrations

Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions

Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands

ACE2, angiotensin (1 7) and M as receptor axis in inflammation and fibrosis

Activation of Ang-(1-7)/mas receptor is a possible strategy to treat coronavirus (SARS-CoV-2) infection

Role of the vasodilator peptide angiotensin

Angiotensin-(1-7) decreases cell growth and angiogenesis of human nasopharyngeal carcinoma xenografts

Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor

Angiotensin (1 7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt 1

Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats

Kidney impairment is associated with in-hospital death of COVID-19 patients

ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension

Suppressing inflammation by inhibiting the NF κB pathway contributes to the neuroprotective effect of angiotensin (1 7) in rats with permanent cerebral ischaemia

Lentivirus mediated overexpression of angiotensin (1-7) attenuated ischaemia induced cardiac pathophysiology

The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets

Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2−/− mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation

Antithrombotic effect of captopril and losartan is mediated by angiotensin

The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets

Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin

Selective activation of angiotensin AT 2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis

Protective role of the ACE2/Ang-(1-9) axis in cardiovascular remodeling

Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro

-9) preserves left ventricular systolic function after myocardial infarction

Angiotensin1 9 antagonises pro hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor

Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis

Erd s, Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A

Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor

Angiotensin-(1-9) reduces cardiovascular and renal inflammation in experimental reninindependent hypertension

Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor

Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma

Apelinergic system structure and function

Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release

Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity

Chronic central administration of apelin 13 over 10 days increases food intake, body weight, locomotor activity and body temperature in C57BL/6 mice

Apelin and its receptor APJ in cardiovascular diseases

Effects of Apelin on Left Ventricular-Arterial Coupling and Mechanical Efficiency in Rats with Ischemic Heart Failure

Apelin increases cardiac contractility via protein kinase Cε-and extracellular signal-regulated kinase-dependent mechanisms

Post-infarct treatment with [Pyr1] apelin-13 improves myocardial function by increasing neovascularization and overexpression of angiogenic growth factors in rats

Novel pathogenesis: regulation of apoptosis by Apelin/APJ system

Hypoxiainduced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis

Apln-CreERT: mT/mG reporter mice as a tool for sprouting angiogenesis study

Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1α, SDF-1α and VEGF-B

Hypoxia induces the proliferation of endothelial progenitor cells via upregulation of Apelin/APLNR/MAPK signaling

Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials

Apelin/APJ signaling promotes hypoxia-induced proliferation of endothelial progenitor cells via phosphoinositide-3 kinase/Akt signaling

Temporal effect of Guanxin No. 2 on cardiac function, blood viscosity and angiogenesis in rats after long-term occlusion of the left anterior descending coronary artery

Apelin attenuates oxidative stress in human adipocytes

Structural apelin analogues: mitochondrial ROS inhibition and cardiometabolic protection in myocardial ischaemia reperfusion injury

Effect of apelin hormone on renal ischemia/reperfusion induced oxidative damage in rats

Apelin-13 administration protects against LPS-induced acute lung injury by inhibiting NF-κB pathway and NLRP3 inflammasome activation

The Apelin-APJ axis is an endogenous counterinjury mechanism in experimental acute lung injury

The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans inhibition

Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: physiological effects in the cardiovascular system

Apelin is a positive regulator of ACE2 in failing hearts

The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism

Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin

-12) is a biologically active ACE2 metabolite of the endogenous cardiovascular peptide

Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist

Vascular effects of apelin in vivo in man

Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload

Pal'keeva, Effects of structural analogues of apelin-12 in acute myocardial infarction in rats

Pal'keeva, In vivo reduction of reperfusion injury to the heart with apelin-12 peptide in rats

Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis

Myocardial injury and COVID-19: Possible mechanisms

Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance

Angiotensin-converting enzyme-2: a molecular and cellular perspective, Cellular and molecular life sciences

Antinociceptive effects of dynorphin peptides in a model of inflammatory pain

Dynorphin: friend or foe?

Intrathecal dynorphin A1-13 and dynorphin A3-13 reduce rat spinal cord blood flow by non-opioid mechanisms

Non-opioid effects of dynorphins: possible role of the NMDA receptor

Dynorphin A (1-13) neurotoxicity in vitro: opioid and nonopioid mechanisms in mouse spinal cord neurons

Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study

Neurologic manifestations of hospitalized patients with coronavirus disease

Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry

A New Symptom of COVID 19: Loss of Taste and Smell

Methionine-enkephalin-and Dynorphin A-release from immune cells and control of inflammatory pain

Blocking IL-1 to prevent respiratory failure in COVID-19

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

An HPLC/RIA method for dynorphin A1-13 and its main metabolites in human blood

Metabolism of dynorphin A1-13 in human CSF

Metabolism of dynorphin A 1-13 in human blood and plasma

Blocking of Type 1 Angiotensin II Receptor Inhibits T-lymphocyte Activation and IL-2 Production

Signaling and function of interleukin-2 in T lymphocytes

Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin ii-induced inflammation

Regulation of T-cell function by endogenously produced angiotensin II

Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury

Angiotensin II regulates Th1 T cell differentiation through angiotensin II type 1 receptor-PKA-mediated activation of proteasome

The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system

Effects of (Pyr1) apelin-13 on the proliferation and activation of Jarkat T lymphocyte, Xi bao yu fen zi mian yi xue za zhi=

Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum

Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages

Role of angiotensin II type 1 receptor in angiotensin II-induced cytokine production in macrophages

cAMP modulates macrophage development by suppressing M-CSF-induced MAPKs activation

Role of a small molecule in the modulation of cell death signal transduction pathways

Apelin-13 impedes foam cell formation by activating Class III PI3K/Beclin-1-mediated autophagic pathway

Activation and suppression of renin-angiotensin system in human dendritic cells

Is NF κB the sensor of oxidative stress?

Angiotensin II regulates dendritic cells through activation of NF-κB/p65, ERK1/2 and STAT1 pathways

The opioid peptide dynorphin A induces leukocyte responses via integrin Mac-1 (αMβ2, CD11b/CD1 )

Role of the receptor Mas in macrophage-mediated inflammation in vivo

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and metaanalysis

Increased TNF-α-induced apoptosis in lymphocytes from aged humans: changes in TNF-α receptor expression and activation of caspases

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)

Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection

Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells

Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment

Preventing a covid-19 pandemic

Serum apelin 13 levels in patients with pulmonary embolism

IL (Interleukin)-1β, TNF (Tumor Necrosis Factor) α, and Thrombin Directly Induce Capillary Tube Regression

Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography

COVID-19 and central nervous system: Entry routes and

COVID-19: consider cytokine storm syndromes and immunosuppression

Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies, Zhonghua shao shang za zhi= Zhonghua shaoshang zazhi=

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians

Angiotensin converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients

Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and metaanalysis

Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients

Lupus anticoagulant is frequent in patients with Covid 19: Response to Reply

von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins

von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models

Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?

Angiotensin II Type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo

Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone

Differential biotransformation of dynorphin A (1-17) and dynorphin A (1-13) peptides in human blood, ex vivo

Specific receptor for the opioid peptide dynorphin: structure--activity relationships

An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension

Flow activation of AMP-activated protein kinase in vascular endothelium leads to Kruppel-like factor 2 expression

Apelin attenuates hyperoxic lung and heart injury in neonatal rats

Micro RNA 503 promotes angiotensin II induced cardiac fibrosis by targeting Apelin 13

Acute cardiovascular effects of apelin in humans

Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse

The regulatory peptide apelin: a novel inhibitor of renal interstitial fibrosis

Apelin-13 attenuates ER stressmediated neuronal apoptosis by activating Gαi/Gαq-CK2 signaling in ischemic stroke

Protective effect of neuropeptide apelin-13 on 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y dopaminergic cells: involvement of its antioxidant and antiapoptotic properties

Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats

Modification of the terminal residue of apelin-13 antagonizes its hypotensive action

Apelin increases contractility in failing cardiac muscle

Signaling pathways of a structural analogue of apelin-12 involved in myocardial protection against ischemia/reperfusion injury

Apelin-12 exerts neuroprotective effect against ischemia-reperfusion injury by inhibiting JNK and P38MAPK signaling pathway in mouse